Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3758674
Max Phase: Preclinical
Molecular Formula: C24H37ClN4O3S
Molecular Weight: 497.11
Molecule Type: Small molecule
Associated Items:
ID: ALA3758674
Max Phase: Preclinical
Molecular Formula: C24H37ClN4O3S
Molecular Weight: 497.11
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CC2CCN(C(=S)C(C)C)CC2)C[C@H]1OC
Standard InChI: InChI=1S/C24H37ClN4O3S/c1-15(2)24(33)29-9-5-16(6-10-29)13-28-8-7-20(22(14-28)32-4)27-23(30)17-11-18(25)19(26)12-21(17)31-3/h11-12,15-16,20,22H,5-10,13-14,26H2,1-4H3,(H,27,30)/t20-,22+/m0/s1
Standard InChI Key: LATYJVJEPRDPLZ-RBBKRZOGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 497.11 | Molecular Weight (Monoisotopic): 496.2275 | AlogP: 3.45 | #Rotatable Bonds: 7 |
Polar Surface Area: 80.06 | Molecular Species: BASE | HBA: 6 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 9.03 | CX LogP: 2.49 | CX LogD: 0.86 |
Aromatic Rings: 1 | Heavy Atoms: 33 | QED Weighted: 0.44 | Np Likeness Score: -0.89 |
1. Park JS, Im W, Choi S, Park SJ, Jung JM, Baek KS, Son HP, Sharma S, Kim IS, Jung YH.. (2016) Discovery and SAR of N-(1-((substituted piperidin-4-yl)methyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide derivatives: 5-Hydroxytryptamine receptor 4 agonist as a potent prokinetic agent., 109 [PMID:26761776] [10.1016/j.ejmech.2015.12.006] |
Source(1):